文献速递中医内科中药与中成药合理使用针灸推拿

中医药治疗脑小血管病:疗效与潜在机制综述

Traditional Chinese medicine as a therapeutic option for cerebral small vessel disease: treatment outcomes and potential mechanisms.
PubMed 文献 · J Ethnopharmacol · 2026-04-17

基于临床试验、动物模型和体外研究,中医药可能通过保护内皮、稳定血脑屏障、抗神经炎症、改善微循环和促进淋巴清除等途径获益,但多数研究样本量小、周期短,标准化和可重复性障碍仍需进一步研究。

要点

  • 中医药可能通过多靶点保护内皮、稳定血脑屏障、抗炎、改善微循环等机制干预CSVD。
  • 部分特定方剂在临床试验中显示可改善认知和日常生活能力,尤其对认知障碍患者。
  • 现有证据多为临床前研究且样本量小、周期短,需更大规模临床试验验证。

核心结论

  • 中医药可能针对CSVD相关的复杂网络发挥作用,特定方剂显示改善内皮功能、降低血脑屏障通透性、减轻神经炎症、改善低灌注和促进代谢废物清除的能力。
  • 现代制剂技术提高中药的精准性和疗效,但标准化和可重复性障碍需进一步研究以促进临床转化和广泛接受。

研究设计与样本

  • 纳入文献为合格的原始研究(包括临床试验、观察性研究和涉及人类或动物/细胞模型的实验研究),采用任何中医药干预措施并报告疗效、机制或安全性相关结局指标;排除综述、评论和病例报告。
  • 由两名评价者独立筛选标题、摘要和全文,分歧通过共识协商或第三名评价者解决;因纳入研究间异质性显著,未进行Meta分析。
  • 采用Cochrane偏倚风险评估工具评价临床研究质量,采用SYRCLE偏倚风险评估工具评价动物研究质量,评估结果用于辅助解释研究结果而非排除研究。

主要发现

  • 基于临床试验、动物模型和体外研究,本综述描述了多种可能使CSVD患者获益的中医药疗法,这些疗法保护内皮、稳定血脑屏障、减少神经炎症、增加微循环和清除淋巴。
  • 动物模型显示中药复方通过PI3K/Akt、NF-κB和Wnt/β-catenin通路调节血管稳态和减少白质损伤。
  • 一些临床研究表明特定方剂可提高认知和日常生活能力,表明其治疗疗效,尤其在认知障碍或神经退行性疾病患者中。
  • 许多实验样本量有限且持续时间短;现代制剂提高药物吸收和脑靶向性,但大多数研究为临床前研究;机制多样但证据不一。

临床怎么用

  • 中医药可作为CSVD的潜在辅助治疗选项,尤其对认知障碍患者,但需在更大规模临床试验验证前谨慎使用。
  • 临床决策应结合现有证据的局限性,关注特定方剂对内皮功能、血脑屏障和神经炎症的潜在作用。

局限性

  • 许多实验样本量有限且持续时间短。
  • 大多数研究为临床前研究,需临床验证。
  • 机制多样但证据强度不一。
  • 标准化和可重复性存在障碍。
  • 因研究间异质性显著未进行Meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Cerebral small vessel disease (CSVD) leads to vascular cognitive impairment, gait disturbances, and disability in later life. Common observations include white matter hyperintensities, lacunar infarcts, increased perivascular gaps, and microhemorrhages. The condition progresses gradually as a result of endothelial and microvascular dysfunction, diminished blood flow, compromised lymphatic clearance, and neuroinflammation. Contemporary medicine has enhanced risk management; yet, no medication substantially postpones disease progression, underscoring the necessity for alternative treatment strategies. Traditional Chinese Medicine (TCM), characterized by its holistic approach and classification of conditions, provides a distinctive perspective on complex diseases, including cerebral small vessel disease. In TCM, theories such as "blood stasis obstructing collaterals", "toxin impairing collaterals" and "kidney deficiency leading to marrow degeneration" are highly consistent with the contemporary pathophysiological theories of CSVD. This review uniquely synthesizes TCM theories with contemporary mechanistic evidence, encompassing clinical trials and network pharmacology, thereby establishing a comprehensive framework for the prospective application of TCM in CSVD and filling a void in prior research in this domain. AIM OF THE STUDY: This study assesses TCM for CSVD, elucidates its mechanisms of action and clinical efficacy, and synthesizes recent research to evaluate TCM's significance and potential in the management of CSVD. MATERIALS AND METHODS: In accordance with the PRISMA guidelines, we conducted a systematic search of major scientific databases (PubMed, Web of Science, Embase, Cochrane Library, Wanfang and CNKI), with the search time range spanning from the establishment of each database to October 2025. Predefined keywords were adopted, including cerebral small vessel disease, white matter hyperintensities, lacunar cerebral infarction, traditional Chinese medicine, Chinese herbal medicine, acupuncture, and traditional Chinese herbal prescriptions. The literatures included in the analysis were qualified original studies (covering clinical trials, observational studies, and experimental studies involving human subjects or animal/cell models). These studies adopted any intervention measures of TCM and reported outcome indicators related to efficacy, mechanisms or safety. Reviews, commentaries and case reports were excluded. Two reviewers independently screened the titles, abstracts and full texts. Discrepancies were resolved through consensus negotiation or by a third reviewer. Standardized forms were used for data extraction. Meta-analysis was not performed due to the significant heterogeneity among the included studies. The quality of clinical studies was evaluated using the Cochrane Risk of Bias Assessment Tool, and the quality of animal studies was assessed with the SYRCLE Risk of Bias Assessment Tool. The evaluation results were applied to assist in interpreting the research findings, rather than serving as the basis for excluding relevant studies. RESULTS: Based on clinical trials, animal models, and in vitro investigations, this study describes several TCM therapies that may benefit CSVD. These therapies protect the endothelium, stabilize the BBB, reduce neuroinflammation, increase microcirculation, and clear lymphatics. These effects match CSVD's complex pathology, but the research deserves scrutiny. Animal models have shown that TCM formulations regulate vascular homeostasis and reduce white matter injury via PI3K/Akt, NF-κB, and Wnt/β-catenin pathways. These interesting discoveries need clinical validation to be relevant. However, some clinical investigations demonstrate that specific formulations increase cognition and daily life, indicating their therapeutic efficacy, particularly in patients with cognitive impairments or neurodegenerative conditions. Numerous experiments have limited sample sizes and short durations. Modern formulations increase drug absorption and brain targeting, yet most research is preclinical. Mechanisms are diverse, but evidence varies. Confirming these preliminary findings requires larger, more thorough clinical investigations. CONCLUSION: In conclusion, TCM may target the intricate network associated with persistent stroke-related vascular illness. Specific herbal formulations have demonstrated the ability to enhance endothelial function and diminish blood-brain barrier (BBB)permeability. They additionally mitigate neuroinflammation, enhance hypoperfusion, and facilitate the clearance of metabolic waste. Contemporary formulation techniques improve the precision and efficacy of TCM. Collectively, these data indicate novel approaches for the management of CSVD as a chronic condition. Nonetheless, obstacles in standardization and reproducibility necessitate additional investigation to facilitate clinical translation and wider acceptability.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Bao X, Zhang Z, Bai X, et al. Traditional Chinese medicine as a therapeutic option for cerebral small vessel disease: treatment outcomes and potential mechanisms. J Ethnopharmacol. 2026. PMID: 42002118. doi:10.1016/j.jep.2026.121707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。